Insider Selling: Merck & Co. EVP Sells 22,000 Shares of Stock (MRK)
Merck & Co. (NYSE:MRK) EVP Adam H. Schechter unloaded 22,000 shares of the stock on the open market in a transaction that occurred on Monday, August 25th. The shares were sold at an average price of $59.70, for a total transaction of $1,313,400.00. The sale was disclosed in a document filed with the SEC, which can be accessed through this link.
Merck & Co. (NYSE:MRK) traded up 0.95% on Monday, hitting $59.73. The stock had a trading volume of 5,093,681 shares. Merck & Co. has a 1-year low of $44.62 and a 1-year high of $59.84. The stock’s 50-day moving average is $57.89 and its 200-day moving average is $57.00. The company has a market cap of $172.3 billion and a price-to-earnings ratio of 31.17.
Merck & Co. (NYSE:MRK) last posted its quarterly earnings results on Tuesday, July 29th. The company reported $0.85 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.80 by $0.05. The company had revenue of $10.93 billion for the quarter, compared to the consensus estimate of $10.60 billion. During the same quarter in the prior year, the company posted $0.84 earnings per share. The company’s quarterly revenue was down .7% on a year-over-year basis. Analysts expect that Merck & Co. will post $3.49 EPS for the current fiscal year.
The company also recently announced a quarterly dividend, which is scheduled for Tuesday, October 7th. Stockholders of record on Monday, September 15th will be paid a dividend of $0.44 per share. This represents a $1.76 annualized dividend and a dividend yield of 2.97%. The ex-dividend date is Thursday, September 11th.
A number of research firms have recently commented on MRK. Analysts at Zacks reiterated a “neutral” rating on shares of Merck & Co. in a research note on Monday, August 18th. They now have a $62.00 price target on the stock. Separately, analysts at Jefferies Group cut their price target on shares of Merck & Co. from $63.00 to $60.00 in a research note on Monday, August 11th. They now have a “hold” rating on the stock. Finally, analysts at Credit Suisse reiterated a “neutral” rating on shares of Merck & Co. in a research note on Thursday, July 31st. They now have a $59.00 price target on the stock, up previously from $56.00. Seven research analysts have rated the stock with a hold rating and seven have issued a buy rating to the company. The company presently has an average rating of “Buy” and a consensus target price of $60.64.
Merck & Co, Inc (NYSE:MRK), is a global health care company that delivers health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products, which it markets directly and through its joint ventures.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.